Posted by Michael Wonder on 12 Dec 2017
Final NHS ‘no’ for obesity pill Mysimba
12 December 2017 - An appeal to get NHS funding for Mysimba as a means for controlling weight has failed, with cost-regulators publishing final guidelines rejecting the drug.
The National Institute for Health and Care Excellence is not recommending Mysimba (naltrexone–bupropion) within its marketing authorisation for managing overweight and obesity in adults alongside a reduced-calorie diet and increased physical activity.
According to the Institute, while clinical trial evidence shows that a combination of the drug and lifestyle measures is more effective than lifestyle measures alone, its long-term effectiveness is unknown.
